Article | Published:

Targeted delivery of nitric oxide via a ‘bump-and-hole’-based enzyme–prodrug pair

Nature Chemical Biologyvolume 15pages151160 (2019) | Download Citation

Abstract

The spatiotemporal generation of nitric oxide (NO), a versatile endogenous messenger, is precisely controlled. Despite its therapeutic potential for a wide range of diseases, NO-based therapies are limited clinically due to a lack of effective strategies for precisely delivering NO to a specific site. In the present study, we developed a novel NO delivery system via modification of an enzyme–prodrug pair of galactosidase–galactosyl-NONOate using a ‘bump-and-hole’ strategy. Precise delivery to targeted tissues was clearly demonstrated by an in vivo near-infrared imaging assay. The therapeutic potential was evaluated in both rat hindlimb ischemia and mouse acute kidney injury models. Targeted delivery of NO clearly enhanced its therapeutic efficacy in tissue repair and function recovery and abolished side effects due to the systemic release of NO. The developed protocol holds broad applicability in the targeted delivery of important gaseous signaling molecules and offers a potent tool for the investigation of relevant molecular mechanisms.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Data availability

The data that support the findings of this study are available within the article and supplementary information files and from the corresponding authors upon reasonable request.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Förstermann, U. & Sessa, W. C. Nitric oxide synthases: regulation and function. Eur. Heart J. 33, 829–837, 837a–837d (2012).

  2. 2.

    SoRelle, R. Nobel prize awarded to scientists for nitric oxide discoveries. Circulation 98, 2365–2366 (1998).

  3. 3.

    de Carvalho, M. P., Weich, H. & Abraham, W.-R. Macrocyclic trichothecenes as antifungal and anticancer compounds. Curr. Med. Chem. 23, 23–35 (2016).

  4. 4.

    Miller, M. R. & Megson, I. L. Recent developments in nitric oxide donor drugs. Br. J. Pharmacol. 151, 305–321 (2007).

  5. 5.

    Baek, S. H. et al. Augmentation of intrapericardial nitric oxide level by a prolonged-release nitric oxide donor reduces luminal narrowing after porcine coronary angioplasty. Circulation 105, 2779–2784 (2002).

  6. 6.

    Kapadia, M. R. et al. Nitric oxide and nanotechnology: a novel approach to inhibit neointimal hyperplasia. J. Vasc. Surg. 47, 173–182 (2008).

  7. 7.

    Bogdan, C. Nitric oxide and the immune response. Nat. Immunol. 2, 907–916 (2001).

  8. 8.

    Mazzone, M. & Carmeliet, P. Drug discovery: a lifeline for suffocating tissues. Nature 453, 1194–1195 (2008).

  9. 9.

    Kashiwagi, S. et al. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J. Clin. Invest. 115, 1816–1827 (2005).

  10. 10.

    Lundberg, J. O., Weitzberg, E. & Gladwin, M. T. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat. Rev. Drug. Discov. 7, 156–167 (2008).

  11. 11.

    Hrabie, J. A. & Keefer, L. K. Chemistry of the nitric oxide-releasing diazeniumdiolate (“nitrosohydroxylamine”) functional group and its oxygen-substituted derivatives. Chem. Rev. 102, 1135–1154 (2002).

  12. 12.

    Wu, X., Tang, X., Xian, M. & Wang, P. G. Glycosylated diazeniumdiolates: a novel class of enzyme-activated nitric oxide donors. Tetrahedr. Lett. 42, 3779–3782 (2001).

  13. 13.

    Zhao, Q. et al. Polysaccharide-based biomaterials with on-demand nitric oxide releasing property regulated by enzyme catalysis. Biomaterials. 34, 8450–8458 (2013).

  14. 14.

    Wang, Z. et al. Enzyme-functionalized vascular grafts catalyze in-situ release of nitric oxide from exogenous NO prodrug. J. Control Release 210, 179–188 (2015).

  15. 15.

    Chandrawati, R. et al. Localized and controlled delivery of nitric oxide to the conventional outflow pathway via enzyme biocatalysis: toward therapy for glaucoma. Adv. Mater. 29, 1604932 (2017).

  16. 16.

    Chandrawati, R. et al. Enzyme prodrug therapy engineered into electrospun fibers with embedded liposomes for controlled, localized synthesis of therapeutics. Adv. Healthc. Mater. 6, 1700385 (2017).

  17. 17.

    Lundberg, J. O., Gladwin, M. T. & Weitzberg, E. Strategies to increase nitric oxide signalling in cardiovascular disease. Nat. Rev. Drug. Discov. 14, 623–641 (2015).

  18. 18.

    Springer, C. J. & Niculescu-Duvaz, I. Antibody-directed enzyme prodrug therapy (ADEPT): a review. Adv. Drug Deliv. Rev. 26, 151–172 (1997).

  19. 19.

    Städler, B. & Zelikin, A. N. Enzyme prodrug therapies and therapeutic enzymes. Adv. Drug Deliv. Rev. 118, 1 (2017).

  20. 20.

    Walther, R., Rautio, J. & Zelikin, A. N. Prodrugs in medicinal chemistry and enzyme prodrug therapies. Adv. Drug Deliv. Rev. 118, 65–77 (2017).

  21. 21.

    Shah, K., Liu, Y., Deirmengian, C. & Shokat, K. M. Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates. Proc. Natl Acad. Sci. USA 94, 3565–3570 (1997).

  22. 22.

    Bishop, A. C. et al. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 407, 395–401 (2000).

  23. 23.

    Baud, M. G. J. et al. Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes. Science 346, 638–641 (2014).

  24. 24.

    Baud, M. G., Lin-Shiao, E., Zengerle, M., Tallant, C. & Ciulli, A. New synthetic routes to triazolo-benzodiazepine analogues: expanding the scope of the bump-and-hole approach for selective bromo and extra-terminal (BET) bromodomain inhibition. J. Med. Chem. 59, 1492–1500 (2016).

  25. 25.

    Islam, K. et al. Defining efficient enzyme-cofactor pairs for bioorthogonal profiling of protein methylation. Proc. Natl Acad. Sci. USA 110, 16778–16783 (2013).

  26. 26.

    Cai, T. B., Lu, D., Landerholm, M. & Wang, P. G. Sialated diazeniumdiolate: a new sialidase-activated nitric oxide donor. Org. Lett. 6, 4203–4205 (2004).

  27. 27.

    Nagano, T. & Yoshimura, T. Bioimaging of nitric oxide. Chem. Rev. 102, 1235–1270 (2002).

  28. 28.

    Sabbisetti, V. S. et al. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J. Am. Soc. Nephrol. 25, 2177–2186 (2014).

  29. 29.

    Portilla, D. et al. Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int. 69, 2194–2204 (2006).

  30. 30.

    Vaziri, N. D. HDL abnormalities in nephrotic syndrome and chronic kidney disease. Nat. Rev. Nephrol. 12, 37–47 (2016).

  31. 31.

    LeBleu, V. S. et al. Origin and function of myofibroblasts in kidney fibrosis. Nat. Med. 19, 1047–1053 (2013).

  32. 32.

    Sun, Y. B. Y., Qu, X., Caruana, G. & Li, J. The origin of renal fibroblasts/myofibroblasts and the signals that trigger fibrosis. Differentiation 92, 102–107 (2016).

  33. 33.

    Liu, Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 69, 213–217 (2006).

  34. 34.

    Feng, G. et al. IGF-1 C domain-modified hydrogel enhances cell Therapy for AKI. J. Am. Soc. Nephrol. 27, 2357–2369 (2016).

  35. 35.

    Chiazza, F. et al. A nitric oxide-donor furoxan moiety improves the efficacy of edaravone against early renal dysfunction and injury evoked by ischemia/reperfusion. Oxid. Med. Cell Longev. 2015, 804659 (2015).

  36. 36.

    Yuen, D. A. et al. eNOS deficiency predisposes podocytes to injury in diabetes. J. Am. Soc. Nephrol. 23, 1810–1823 (2012).

  37. 37.

    Cheng, H. et al. Synthesis and enzyme-specific activation of carbohydrate-geldanamycin conjugates with potent anticancer activity. J. Med. Chem. 48, 645–652 (2005).

  38. 38.

    Bolam, D. N. et al. The crystal structure of two macrolide glycosyltransferases provides a blueprint for host cell antibiotic immunity. Proc. Natl Acad. Sci. USA 104, 5336–5341 (2007).

  39. 39.

    Ramakrishnan, B. & Qasba, P. K. Structure-based design of β1,4-galactosyltransferase I (β4Gal-T1) with equally efficient N-acetylgalactosaminyltransferase activity: point mutation broadens β4Gal-T1 donor specificity. J. Biol. Chem. 277, 20833–20839 (2002).

  40. 40.

    Uchida, N. et al. Chemical hijacking of auxin signaling with an engineered auxin-TIR1 pair. Nat. Chem. Biol. 14, 299–305 (2018).

  41. 41.

    Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932–936 (2005).

  42. 42.

    Cao, R. et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat. Med. 9, 604–613 (2003).

  43. 43.

    Place, E. S., Evans, N. D. & Stevens, M. M. Complexity in biomaterials for tissue engineering. Nat. Mater. 8, 457–470 (2009).

  44. 44.

    Cooke, J. P. NO and angiogenesis. Atheroscler. Suppl. 4, 53–60 (2003).

  45. 45.

    Ziche, M. et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J. Clin. Invest. 94, 2036–2044 (1994).

  46. 46.

    Jain, R. K. Molecular regulation of vessel maturation. Nat. Med. 9, 685–693 (2003).

  47. 47.

    Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958–969 (2008).

  48. 48.

    Khambata, R. S. et al. Antiinflammatory actions of inorganic nitrate stabilize the atherosclerotic plaque. Proc. Natl Acad. Sci. USA 114, E550–E559 (2017).

  49. 49.

    Liu, V. W. & Huang, P. L. Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice. Cardiovasc. Res. 77, 19–29 (2008).

  50. 50.

    Berg, J. D. & Fiksdal, L. Rapid detection of total and fecal coliforms in water by enzymatic hydrolysis of 4-methylumbelliferone-β-d-galactoside. Appl. Environ. Microbiol. 54, 2118–2122 (1988).

  51. 51.

    Huber, R. E., Hakda, S., Cheng, C., Cupples, C. G. & Edwards, R. A. Trp-999 of β-galactosidase (Escherichia coli) is a key residue for binding, catalysis, and synthesis of allolactose, the natural lac operon inducer. Biochemistry 42, 1796–1803 (2003).

  52. 52.

    Shinobu, L. A., Jones, S. G. & Jones, M. M. Sodium N-methyl-d-glucamine dithiocarbamate and cadmium intoxication. Acta Pharmacol. Toxicol. (Copenh.) 54, 189–194 (1984).

  53. 53.

    Ricles, L. M. et al. Therapeutic assessment of mesenchymal stem cells delivered within a PEGylated fibrin gel following an ischemic injury. Biomaterials. 102, 9–19 (2016).

  54. 54.

    Du, W. et al. Enhanced proangiogenic potential of mesenchymal stem cell-derived exosomes stimulated by a nitric oxide releasing polymer. Biomaterials. 133, 70–81 (2017).

  55. 55.

    Kinnaird, T. et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 109, 1543–1549 (2004).

Download references

Acknowledgements

We thank J. Xiao at Shanghai University for kindly donating eNOS-knockout mice. This study was supported by National Natural Science Foundation of China (Nos. 81522023 to Q.Z., 81830060 to D.K., 81603064 to J.H., 81871500 to Q.Z., and 91639113 to Q.Z.) and National Key R&D Program of China (2017YFC1103501 to D.K. and Q.Z.).

Author information

Author notes

  1. These authors contributed equally: Jingli Hou, Yiwa Pan, Dashuai Zhu.

Affiliations

  1. State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China

    • Jingli Hou
    • , Yueyuan Fan
    • , Jiansong Cheng
    •  & Jie Shen
  2. Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, PR China

    • Jingli Hou
    •  & Yangping Liu
  3. State key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials, Ministry of Education, and College of Life Science, Nankai University, Tianjin, China

    • Yiwa Pan
    • , Yongzhen Wei
    • , He Wang
    • , Kang Qin
    • , Deling Kong
    •  & Qiang Zhao
  4. School of Medicine, Nankai University, Tianjin, China

    • Dashuai Zhu
    •  & Yongzhe Che
  5. Department of Genitourinary Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

    • Guowei Feng
  6. Center for Research and Development of Chinese Medicine, Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China

    • Tiechan Zhao
    •  & Yan Zhu
  7. Spine Department, Tianjin Hospital, Tianjin, China

    • Qiang Yang
  8. Department of Chemistry and Center for Therapeutics and Diagnostics, Georgia State University, Atlanta, GA, USA

    • Peng George Wang
  9. Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China

    • Qiang Zhao

Authors

  1. Search for Jingli Hou in:

  2. Search for Yiwa Pan in:

  3. Search for Dashuai Zhu in:

  4. Search for Yueyuan Fan in:

  5. Search for Guowei Feng in:

  6. Search for Yongzhen Wei in:

  7. Search for He Wang in:

  8. Search for Kang Qin in:

  9. Search for Tiechan Zhao in:

  10. Search for Qiang Yang in:

  11. Search for Yan Zhu in:

  12. Search for Yongzhe Che in:

  13. Search for Yangping Liu in:

  14. Search for Jiansong Cheng in:

  15. Search for Deling Kong in:

  16. Search for Peng George Wang in:

  17. Search for Jie Shen in:

  18. Search for Qiang Zhao in:

Contributions

J.S. and J.C. conceived the original concept and initiated this project. Q.Z. designed the experiment and supervised the entire project. Y.F. performed the expression of enzymes under the supervision of J.C. J.H. carried out the synthesis of all compounds and fluorescent probes. G.F. established ischemia animal models. Y.P. and D.Z. performed the in vivo evaluation and analyzed data under the supervision of Q.Z. J.H. and H.W. performed the in vitro releasing test of NO. Y.W. carried out the RT-PCR assay. T.Z. performed micro-CT analysis under the supervision of Y.Z. Y.L. helped with EPR analysis. K.Q., Y.C., and Q.Y. helped with data collection. P.G.W. and D.K. provided critical feedback and helped in review of the article. Q.Z., J.C., and J.H. wrote the paper with input from other authors.

Competing interests

The authors declare no competing interests.

Corresponding authors

Correspondence to Jiansong Cheng or Jie Shen or Qiang Zhao.

Supplementary information

  1. Supplementary Text and Figures

    Supplementary Tables 1–5, Supplementary Figures 1–17

  2. Reporting Summary

  3. Supplementary Note 1

    Synthetic Procedures

About this article

Publication history

Received

Accepted

Published

Issue Date

DOI

https://doi.org/10.1038/s41589-018-0190-5